Transition Therapeutics (TTHI) Reports Q1 Loss of $0.12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall St choppy as megacap losses offset chip gains before Fed decision
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise about 2% as Yemen fighting stokes supply fears
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- S&P Global explores potential separation of Capital IQ business
- SpaceX stock drops amid spaceport lawsuit, debt concerns
- Wall Street ends higher on revived AI momentum
- Nebius Group shares jump after France data center funding
- GE Vernova Inc. (GEV) Tops Q3 EPS by 81c, Beats on Revenue; Offers FY26 Revenue Guidance
Transition Therapeutics Announces First Quarter Fiscal 2016 Financial Results
November 10, 2015 4:01 PM ESTTORONTO, Nov. 10, 2015 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the three month period ended September 30, 2015. Investors are invited to participate in a conference call today at 4:30pm EST to discuss these results.  Dial in information for the call is as follows: (888) 227-6492 (North America) and (303) 223-2685 (International).  A live webcast can be accessed via Transition's website... More



